NeuroBo Pharmaceuticals, Inc. - NRBO STOCK NEWS

NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, announces participation in two investor conferences this November. Hyung Heon Kim, President and CEO, and Marshall H. Woodworth, CFO, will present company overviews at the Life Science Virtual Investor Forum on November 14 at 1:00 pm ET and the Winter 2024 Investor Summit Virtual on November 21 at 11:00 am ET. Management will be available for one-on-one meetings during both events. Interested parties can register through provided links or contact Michael Miller for meetings outside these events.

NeuroBo Pharmaceuticals reported Q3 2024 financial results and clinical progress. The company announced positive top-line data from the SAD Part 1 Phase 1 trial of DA-1726 for obesity treatment, showing favorable safety and dose-linear pharmacokinetics. With $21.7 million cash on hand, operations are funded into Q3 2025. Key upcoming milestones include top-line results from DA-1241's Phase 2a MASH trial in December 2024 and DA-1726's MAD Part 2 data in Q1 2025. Q3 net loss was $5.7 million, with R&D expenses increasing to $4.5 million compared to $2.3 million in Q3 2023.

NeuroBo Pharmaceuticals has completed the last patient visit in its Phase 2a clinical trial of DA-1241, a GPR119 agonist for treating metabolic dysfunction-associated steatohepatitis (MASH). The trial consists of two parts: Part 1 comparing DA-1241 to placebo, and Part 2 testing DA-1241 combined with sitagliptin. Of 109 randomized patients, 95 completed the 16-week dosing period. The study's primary endpoint is measuring change in ALT levels at Week 16, with topline data expected in December 2024. The drug showed good tolerability in previous Phase 1 studies with healthy volunteers and type 2 diabetes patients.

NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on cardiometabolic diseases, announced its participation in two investor conferences in October 2024:

1. H.C. Wainwright 8th Annual MASH Virtual Conference on October 7: President and CEO Hyung Heon Kim will present a company overview at 11:00 am ET. Management will be available for one-on-one meetings.

2. 2024 Maxim Healthcare Virtual Summit from October 15-17: Kim and CFO Marshall H. Woodworth will participate in a virtual fireside chat on October 15 at 2:30 pm ET.

Investors can register for the H.C. Wainwright conference at https://hcwevents.com/mashconference/. To schedule meetings outside these conferences, contact Michael Miller at mmiller@rxir.com.

NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced positive top-line data from Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study revealed favorable safety, tolerability, and dose-linear pharmacokinetics in 45 obese participants. Key findings include:

- No serious adverse events reported
- Only 5 subjects in the DA-1726 group reported adverse events vs. 3 in placebo
- Dose-linear PK profile observed across investigated dose range
- Additional cohorts being added to explore maximum tolerated dose

The company has initiated the multiple ascending dose (MAD) Part 2 study and expects top-line data in Q1 2025. A planned Part 3 will evaluate early proof of concept. NeuroBo believes DA-1726 could become a best-in-class obesity drug with better tolerability than current GLP-1 agonists.

NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotech company focusing on cardiometabolic diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York.

Key points:

• President and CEO Hyung Heon Kim and CFO Marshall H. Woodworth will present a company overview on September 10 at 1:30 pm ET.
• Management will be available for one-on-one meetings during the conference.
• Institutional investors can register at www.hcwevents.com/annualconference to access the presentation or request meetings.
• For meetings outside the conference, investors can contact Michael Miller at mmiller@rxir.com.

NeuroBo Pharmaceuticals (NRBO) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

• Completed a $70 million financing, with $20 million upfront and $50 million in milestone-based warrants
• $27.9 million cash at quarter-end, expected to fund operations into Q2 2025
• Fully enrolled SAD Part 1 of DA-1726 Phase 1 trial for obesity, with top-line data expected in Q3 2024
• Entered joint research agreement to develop long-acting formulation of DA-1726
• Part 2 of DA-1241 Phase 2a trial for MASH underway, top-line data expected in Q4 2024
• Net loss of $10.1 million for Q2 2024, compared to $0.7 million in Q2 2023

The company is advancing its cardiometabolic pipeline with multiple upcoming milestones for DA-1726 and DA-1241.

NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment for Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study enrolled 45 participants across 5 cohorts. No significant issues were encountered, allowing an accelerated start to the multiple ascending dose (MAD) Part 2.

Key points:

• Top-line data from SAD Part 1 expected in Q3 2024
• MAD Part 2 results anticipated in Q1 2025
• Pre-clinical data showed superior weight loss compared to semaglutide and tirzepatide
• DA-1726 may become a best-in-class obesity drug with better tolerability
• Part 3 of the trial planned to start in Q3 2025, with interim data expected mid-2026 and top-line results in H2 2026

NeuroBo Pharmaceuticals (Nasdaq: NRBO) has entered a joint research agreement with Dong-A ST and ImmunoForge to develop a long-acting, once-monthly formulation of DA-1726 for obesity treatment. DA-1726 is a novel, dual oxyntomodulin analog agonist functioning as a GLP1R and GCGR agonist, currently in Phase 1 studies. The collaboration will utilize ImmunoForge's Elastin-Like Polypeptide (ELP) platform technology, which can potentially increase a drug's half-life by up to 200 times.

This agreement aims to enhance patient compliance and ease of administration for obesity treatment. The ELP technology could overcome limitations in creating longer-acting forms of peptides like DA-1726. The collaboration seeks to develop what could be a first-in-class, once-monthly obesity treatment. Financial terms of the agreement were not disclosed.